DexCom (NASDAQ:DXCM) initiated with Buy rating and $190 (26% upside) price target at Stifel.
Insulet (NASDAQ:PODD) initiated with Hold rating and $163 (8% upside) price target at Stifel.
Senseonics (NYSEMKT:SENS) initiated with Buy rating and $2 (111% upside) price target at Stifel.
Biogen (NASDAQ:BIIB)
upgraded to Buy with a $365 (29% upside) price target at Guggenheim.
Upgraded to Outperform with a $350 price target at SVB Leerink on the
news that it plans to file a U.S. marketing for Alzheimer’s med
aducanumab. Raymond James is not on board, though, saying that the FDA
will give the application the thumbs down. Shares up 2% premarket.
Walgreens Boots Alliance (NASDAQ:WBA) downgraded to Neutral with a $63 (14% upside) price target at JPMorgan. Shares down 1% premarket.
https://seekingalpha.com/news/3508277-sell-siders-upgrade-biogen-aducanumab-prospects-raymond-james-doubts
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.